When the Covid-19 pandemic struck the U.S., young biotech company Verve Therapeutics was just months away from a pivotal development: studies in animals of its gene-editing approach to lowering cholesterol that would lead it to be heralded as a potential “cure for heart disease.”
But Chief Executive Dr. Sekar Kathiresan had a problem: this isn’t the kind of work you can do at home.
